Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
sulfonylurea |
| gptkbp:approvedBy |
1984 (US)
|
| gptkbp:ATCCode |
A10BB07
|
| gptkbp:brand |
Glucotrol
|
| gptkbp:CASNumber |
29094-61-9
|
| gptkbp:contraindication |
gptkb:diabetic_ketoacidosis
type 1 diabetes |
| gptkbp:discoveredBy |
gptkb:Pfizer
|
| gptkbp:drugClass |
second-generation sulfonylurea
|
| gptkbp:eliminationHalfLife |
2–4 hours
|
| gptkbp:excretion |
urine
|
| gptkbp:hasMolecularFormula |
C21H27N5O4S
|
| https://www.w3.org/2000/01/rdf-schema#label |
glipizide
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
stimulates insulin secretion from pancreatic beta cells
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:proteinBinding |
98–99%
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:hypoglycemia
weight gain gastrointestinal upset |
| gptkbp:synonym |
N-[2-(5-methylpyrazine-2-carboxamido)ethyl]benzenesulfonyl-N'-propylurea
|
| gptkbp:usedFor |
gptkb:type_2_diabetes_mellitus
|
| gptkbp:bfsParent |
gptkb:CYP2C9
|
| gptkbp:bfsLayer |
5
|